BRIEF published on 01/27/2025 at 12:35, 1 year 8 months ago NanoViricides Advances NV-387 to Phase II Clinical Trial NanoViricides NV-387 Clinical Trial Antiviral Drug MPOX Treatment
BRIEF published on 01/27/2025 at 12:35, 1 year 8 months ago NanoViricides fait passer le NV-387 à l'essai clinique de phase II NanoViricides NV-387 Essai Clinique Médicament Antiviral Traitement MPox
PRESS RELEASE published on 01/27/2025 at 12:30, 1 year 8 months ago NanoViricides Engages CRO for Phase II Clinical Trial NanoViricides, Inc. engages a Clinical Research Organization for Phase II trial of broad-spectrum antiviral drug NV-387 targeting MPox virus infection. Drug aims to combat viral diseases effectively NanoViricides NV-387 Clinical Trial Antiviral Drug Mpox Virus
BRIEF published on 01/13/2025 at 12:35, 1 year 8 months ago NanoViricides to Present Breakthrough Antiviral Developments at Biotech Showcase NanoViricides NV-387 Biotech Showcase Clinical Trials Antiviral Drugs
BRIEF published on 01/13/2025 at 12:35, 1 year 8 months ago NanoViricides présentera ses avancées antivirales révolutionnaires au Biotech Showcase NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Vitrine Biotechnologique
PRESS RELEASE published on 01/13/2025 at 12:30, 1 year 8 months ago NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 NanoViricides, Inc. to present Phase II-ready drug NV-387 at Biotech Showcase 2025 in San Francisco, demonstrating broad-spectrum antiviral activity against various infections NV-387 NanoViricides Inc. Antiviral Drug San Francisco Biotech Showcase 2025
BRIEF published on 01/08/2025 at 12:35, 1 year 8 months ago Broad-Spectrum Antivirals: A Necessity Amid Multiple Viral Threats NanoViricides NV-387 Broad-spectrum Antivirals RNA Viruses Viral Resistance
BRIEF published on 01/08/2025 at 12:35, 1 year 8 months ago Antiviraux à large spectre : une nécessité face aux multiples menaces virales NanoViricides NV-387 Antiviraux À Large Spectre Virus À ARN Résistance Virale
PRESS RELEASE published on 01/08/2025 at 12:30, 1 year 8 months ago Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals NanoViricides, Inc. President Dr. Anil Diwan comments on multiple pandemic-causing viruses worldwide, highlighting NV-387's broad-spectrum antiviral capabilities NanoViricides NV-387 Antiviral Broad-spectrum Pandemic
BRIEF published on 12/23/2024 at 12:35, 1 year 9 months ago NanoViricides Positions NV-387 as Key Player Against Bird Flu NanoViricides NV-387 Antiviral Drug H5N1 Virus Bird Flu
Published on 09/29/2026 at 15:00, 24 minutes ago As Crisis Events Intensify, BlackBerry and the American Red Cross Renew Commitment to Secure and Trusted Emergency Communications
Published on 09/29/2026 at 14:45, 39 minutes ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Published on 09/29/2026 at 14:30, 54 minutes ago Solitario Resources Presentation Change of Time at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/29/2026 at 14:30, 54 minutes ago Hillcrest ZVS Technology Demonstrates More Than 90% Reduction in Motor Voltage Spikes
Published on 09/29/2026 at 15:12, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/29/2026 at 14:15, 1 hour 9 minutes ago 260929 BENETEAU Mise en oeuvre du programme de rachat d'actions
Published on 09/29/2026 at 12:15, 3 hours 9 minutes ago NRJ GROUP - Affaire Fun Radio - Report du délibéré de la Cour d'appel
Published on 09/29/2026 at 08:45, 6 hours 39 minutes ago Cegedim Santé réinvente l’accès à l’information médicale en déployant l’Assistant by Claude Bernard IA sur toutes ses solutions de médecine de ville
Published on 09/28/2026 at 17:54, 21 hours 29 minutes ago Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 21 hours 29 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
